A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | MicrobiomeTrials
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-08-08Est. Completion: 2032-06-01
Enrollment target: 735 participants
Locations
Highlands Oncology Group ( Site 5405), Springdale, Arkansas, United States
MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach, California, United States
Memorial Hospital West ( Site 5410), Pembroke Pines, Florida, United States
Oregon Health and Science University ( Site 5425), Portland, Oregon, United States
Medical Oncology Associates, PS ( Site 5406), Spokane, Washington, United States
University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423), Madison, Wisconsin, United States
Instituto Alexander Fleming ( Site 1005), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007), Mar del Plata, Buenos Aires, Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Hematology ( Site 1002), Buenos Aires, Buenos Aires F.D., Argentina
Sanatorio Parque ( Site 1003), Rosario, Santa Fe Province, Argentina
Centro Medico Fleischer ( Site 1006), Buenos Aires, Argentina
Hospital Aleman-oncohematologic diseases ( Site 1001), Buenos Aires, Argentina
Royal Adelaide Hospital ( Site 1104), Adelaide, South Australia, Australia
Other microbiome trials you might be interested in